GSK’s HIV, cancer drug sales lift 2025 outlook, boosting shares
By Bhanvi Satija and Yadarisa Shabong LONDON (Reuters) -GSK raised its 2025 sales and profit forecasts on Wednesday as its specialist HIV and cancer drugs posted double-digit growth, lifting the British company’s shares almost 7% to their highest level since May 2024. GSK’s improving outlook comes as Chief Executive Emma Walmsley prepares to hand over…